Height Velocity Percentiles in Indian Children Aged 5-17 Years

Objective: To assess height velocity and develop height velocitypercentiles in 5-17-year-old Indian children; and to study themagnitude and age at peak height velocity.Design: Mixed longitudinal study.Setting: Private schools at Pune and Delhi.Participants/patients: 2949 children (1681 boys) belonging toaffluent class aged 5-17 years (1473-Pune, 1476-Delhi).Methods: Annual height and weight measurements from 2007 to2013. Total 13214 height velocity measurements (7724 on boys).Outcome Measures: Height velocity percentiles (3rd, 10th, 25th,50th, 75th, 90th and 97th) constructed using LMS chart maker.Results: Age- and gender-specific height velocity percentileswere generated. Median height velocity in girls decreased from 5to 8 years, increased to a peak of 6.6 cm at 10.5 years and thendeclined to 0.3 cm at 17.5 years. In boys, median height velocityreduced till 10.5, increased to a peak of 6.8 cms at 13.5 years andthen declined to 1cm by 18 years.Conclusions: Height velocity percentiles in 5-17-year-old urbanIndian children were constructed

Small for gestation and growth hormone therapy.

3 to 10% of neonates are born small for gestation (SGA). This usually occurs because of intrauterine growth retardation (IUGR). After birth most SGA infants show good catch-up growth and normalize their height and weight. About 10% of them continue to remain short (<-2SD) and do not achieve normal adult height, resulting in psychosocial problems. The mechanism of short stature in these children is poorly understood. Infants who do not show catch-up growth usually have an alteration in the GH-IGF-I axis. Diagnostic and management criteria for short stature in SGA were ill-defined in the past. Growth hormone (GH) therapy for improving height in these children has been approved by the FDA. GH therapy leads to growth acceleration and normalization of height during childhood. Long term GH treatment normalizes adult height above -2 SDS in 85% children, and 98% achieve an adult height within their target height range. GH therapy is safe in SGA children, but it is important to monitor for side effects.